- Price
- $18.28
- Day
- -0.54%
- Mkt Cap
- $1.04B
- 52W Range
- $16.67 – $49.90
- Volume
- 3.63M
- Beta
- 0.89
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PROCEPT BioRobotics Corporation (PRCT) Q2 2026 Earnings Call Transcript
Read full article
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (NASDAQ:PRCT) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Procept, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/procept-biorobotics-class-action-lawsuit.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a class action alleging channel stuffing medtech securities fraud has been filed on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026. Find out if you could qualify to recover your losses.
Read full article
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.35 per share a year ago.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive. Should You Join The Procept Class Action Lawsuit : Do you, or did you, own shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT)?
Read full article
SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2026.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read full article
NEW YORK and NEW ORLEANS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NasdaqGM: PRCT), if they purchased the Company's shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”).
Read full article
Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm PR New
Read full article
PROCEPT BioRobotics NASDAQ: PRCT reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. Management said newer HYDROS Robotic System accounts continued to show stronger utilization, supporting an accelerated replacement strategy for older systems.
Read full article
New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact us.
Read full article
New York, New York--(Newsfile Corp. - August 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important September 22, 2026 lead plaintiff deadline. SO WHAT: If you purchased PROCEPT common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read full article